Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center experience.
OBJECTIVE
We retrospectively analyzed the impact of pre- and post-transplant variables on the outcome of transplanta¬tion in 145 consecutive patients with acute myeloblastic leukemia (AML) allografted from their HLA-identical siblings in our single center cohort.


RESULTS
The stem cell source used was bone marrow (BM) (36.6%) or peripheral blood (PB) (63.4%). Both neutrophil and platelet engraftments were observed on the median 14th day. Engraftment was faster in the PB group than in the BM group (p<0.0001). Severe acute graft versus host disease (aGvHD) was observed in 27.9% of the patients while chronic (c)GvHD developed in 61.2%. The use of PB was associated with more severe aGvHD. Estimated leukemia-free survival (LFS) and overall survival (OS) at 10 years were 43.4%±5.2% and 52.7%±4.6%, respectively.


CONCLUSIONS
Both in univariate and multivariate analyses for LFS and OS, remission status at transplant and the presence of aGvHD were independent risk factors.
Department of Hematology, Stem Cell Transplantation Unit, Ankara University Faculty of Medicine, Ankara, Turkey, Tel: +90 312 595 70 99 E-mail: oilhan@superonline.com.
Osman
O
İlhan
Pervin
P
Topçuoğlu
Mutlu
M
Arat
Ender A
EA
Soydan
Meltem K
MK
Yuksel
Önder
Ö
Arslan
Muhit
M
Özcan
Günhan
G
Gürman
Taner
T
Demirer
Hamdi
H
Akan
Nahide
N
Konuk
Akın
A
Uysal